Prime Medicine, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Prime Medicine, Inc. (PRME) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 962.56 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06
- Prime Medicine, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 937.03K shares, a 45.30% decline year-over-year.
- Prime Medicine, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 25.53K shares, a 93.44% decline year-over-year.
- Prime Medicine, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 1.18M shares, a 1040.68% increase year-over-year.
- Prime Medicine, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was 1.71M shares, a 1230.63% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month |
|---|---|---|---|
| 2026-06-30 | 937.03K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 962.56K shares 10-Q · filed 2026-08-06 | |
| 2026-03-31 | 25.53K shares 10-Q · filed 2026-05-07 | ||
| 2025-09-30 | 1.18M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | 2.89M shares derived: sum of 2 quarters · filed 2025-11-07 | 3.28M shares 10-Q · filed 2025-11-07 |
| 2025-06-30 | 1.71M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 2.10M shares 10-Q · filed 2025-08-07 | |
| 2025-03-31 | 389.27K shares 10-Q · filed 2025-05-08 | ||
| 2024-09-30 | 103.49K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 232.24K shares derived: sum of 2 quarters · filed 2024-11-12 | 372.12K shares 10-Q · filed 2024-11-12 |
| 2024-06-30 | 128.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 268.63K shares 10-Q · filed 2024-08-08 | |
| 2024-03-31 | 139.88K shares 10-Q · filed 2024-05-10 | ||
| 2023-09-30 | 82.93K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | 260.08K shares derived: sum of 2 quarters · filed 2023-11-03 | 276.17K shares 10-Q · filed 2023-11-03 |
| 2023-06-30 | 177.15K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 193.23K shares 10-Q · filed 2023-08-07 | |
| 2023-03-31 | 16.09K shares 10-Q · filed 2023-05-11 | ||
| 2022-09-30 | 135.63K shares 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |